Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048451 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT00048451 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 68 participants.
The verdict
NCT00048451, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Interventions
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2002-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048451
The ClinicalTrials.gov registry entry for NCT00048451 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paricalcitol is the first listed.
NCT00048451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048451 about?
NCT00048451 is a clinical study titled "Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)". The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
What is the current status of trial NCT00048451?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2002-02.
What interventions are being tested in trial NCT00048451?
The interventions under investigation include: paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00048451?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.